1. Market Research
  2. > Topotarget A/S – Product Pipeline Review – 2013

Topotarget A/S – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 70 pages

Topotarget A/S – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “TopoTarget A/S - Product Pipeline Review - 2013” provides data on the TopoTarget A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, TopoTarget A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from TopoTarget A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- TopoTarget A/S - Brief TopoTarget A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of TopoTarget A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of TopoTarget A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the TopoTarget A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate TopoTarget A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of TopoTarget A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the TopoTarget A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with TopoTarget A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of TopoTarget A/S and identify potential opportunities in those areas.

Table Of Contents

Topotarget A/S - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Topotarget A/S Snapshot 6
Topotarget A/S Overview 6
Key Information 6
Key Facts 6
Topotarget A/S - Research and Development Overview 7
Key Therapeutic Areas 7
Topotarget A/S - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Topotarget A/S - Pipeline Products Glance 13
Topotarget A/S Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Topotarget A/S - Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Topotarget A/S - Drug Profiles 16
belinostat 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
belinostat + [azacitidine] 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
belinostat + [bortezomib] 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
belinostat + [carboplatin] + [paclitaxel] 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
belinostat + [doxorubicin] 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
TOP-216 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Topotarget A/S - Pipeline Analysis 25
Topotarget A/S - Pipeline Products by Therapeutic Class 25
Topotarget A/S - Pipeline Products by Route of Administration 26
Topotarget A/S - Pipeline Products By Mechanism of Action 27
Topotarget A/S - Recent Pipeline Updates 28
Topotarget A/S - Dormant Projects 33
Topotarget A/S - Locations And Subsidiaries 34
Head Office 34
Other Locations and Subsidiaries 34
Topotarget A/S, Recent Developments 35
Topotarget A/S- Press Release 35
Apr 08, 2013: Topotarget Presents Data From Phase I Study Of Belinostat At AACR 2013 35
Mar 07, 2013: Topotarget Announces Presentation Of Belinostat Clinical Data At 2013 AACR Annual Meeting 35
Mar 05, 2013: TopoTarget's Belinostat Exceeds Primary Endpoint In Pivotal Trial For Patients With Peripheral T-cell Lymphoma 36
Jan 24, 2013: Topotarget's Belinostat Demonstrates Favorable Safety Profile In Phase II Peripheral T-cell Lymphoma Study 37
Dec 23, 2010: Spectrum's Phase II Combination Trial Of Belinostat Meets Enrollment Target 38
Dec 09, 2010: Topotarget A/S Initiates Phase I Study of Belinostat in Combination with Warfarin 38
Nov 18, 2010: Spectrum Presents Four Key Belinostat Abstracts At 52nd Annual Meeting Of ASH 39
May 21, 2010: Spectrum Announces Three Additional Belinostat Abstracts At ASCO 2010 Annual Meeting 39
Mar 22, 2010: Spectrum Announces Dosing Of First Patient In Phase I/II Study Of Belinostat In Thymic Malignancies 41
Feb 02, 2010: Spectrum Pharmaceuticals Licenses Belinostat, A Novel Anticancer Drug In A Pivotal Registrational Trial 42
Financial Deals Landscape 44
Topotarget A/S, Deals Summary 44
Topotarget A/S, Pharmaceuticals and Healthcare, Deal Details 45
Asset Transactions 45
CuraGen Sells Belinostat To TopoTarget 45
Partnerships 48
TopoTarget Enters Into Co-Development Agreement With H. Lundbeck 48
Licensing Agreements 50
TopoTarget Enters Into Licensing Agreement With Oncology Venture For APO010 50
TopoTarget Enters Into Licensing Agreement With Multimeric Biotherapeutics 51
Spectrum Pharma Enters Into Licensing Agreement With TopoTarget 52
BioPro Pharma Enters Into Licensing Agreement With TopoTarget 55
TopoTarget Executes Licensing Option With Novartis Pharma 56
Equity Offering 57
Topotarget Announces Private Placement Of Shares For US$5 Million 57
TopoTarget Completes Rights Offering Of US$24 Million 59
TopoTarget Completes Public Offering Of US$59.32 Million 61
Asset Transactions 63
SpePharm Holding Acquires Rights To Savene From TopoTarget 63
Acquisition 65
Apricus Biosciences Completes Acquisition Of Topotarget USA 65
TopoTarget Acquires Apoxis 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70



List of Tables

Topotarget A/S, Key Information 6
Topotarget A/S, Key Facts 6
Topotarget A/S - Pipeline by Indication, 2013 9
Topotarget A/S - Pipeline by Stage of Development, 2013 10
Topotarget A/S - Monotherapy Products in Pipeline, 2013 11
Topotarget A/S - Combination Treatment Modalities in Pipeline, 2013 12
Topotarget A/S - Phase II, 2013 13
Topotarget A/S - Phase I, 2013 14
Topotarget A/S - Pre-Clinical, 2013 15
Topotarget A/S - Pipeline By Therapeutic Class, 2013 25
Topotarget A/S - Pipeline By Route of Administration, 2013 26
Topotarget A/S - Pipeline Products By Mechanism of Action, 2013 27
Topotarget A/S - Recent Pipeline Updates, 2013 28
Topotarget A/S - Dormant Developmental Projects,2013 33
Topotarget A/S, Subsidiaries 34
Topotarget A/S, Deals Summary 44
CuraGen Sells Belinostat To TopoTarget 45
TopoTarget Enters Into Co-Development Agreement With H. Lundbeck 48
TopoTarget Enters Into Licensing Agreement With Oncology Venture For APO010 50
TopoTarget Enters Into Licensing Agreement With Multimeric Biotherapeutics 51
Spectrum Pharma Enters Into Licensing Agreement With TopoTarget 52
BioPro Pharma Enters Into Licensing Agreement With TopoTarget 55
TopoTarget Executes Licensing Option With Novartis Pharma 56
Topotarget Announces Private Placement Of Shares For US$5 Million 57
TopoTarget Completes Rights Offering Of US$24 Million 59
TopoTarget Completes Public Offering Of US$59.32 Million 61
SpePharm Holding Acquires Rights To Savene From TopoTarget 63
Apricus Biosciences Completes Acquisition Of Topotarget USA 65
TopoTarget Acquires Apoxis 67



List of Figures

Topotarget A/S - Pipeline by Indication, 2013 8
Topotarget A/S - Pipeline by Stage of Development, 2013 10
Topotarget A/S - Monotherapy Products in Pipeline, 2013 11
Topotarget A/S - Combination Treatment Modalities in Pipeline, 2013 12
Topotarget A/S - Pipeline By Route of Administration, 2013 26
Topotarget A/S - Pipeline Products By Mechanism of Action, 2013 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.